Compare · CNMD vs PRKS
CNMD vs PRKS
Side-by-side comparison of CONMED Corporation (CNMD) and United Parks & Resorts Inc. (PRKS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CNMD and PRKS operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- PRKS is the larger of the two at $2.16B, about 1.7x CNMD ($1.30B).
- Over the past year, CNMD is down 9.3% and PRKS is down 6.1% - PRKS leads by 3.2 points.
- PRKS has been more active in the news (12 items in the past 4 weeks vs 9 for CNMD).
- CNMD has more recent analyst coverage (16 ratings vs 8 for PRKS).
- Company
- CONMED Corporation
- United Parks & Resorts Inc.
- Price
- $43.21-4.01%
- $45.04-4.17%
- Market cap
- $1.30B
- $2.16B
- 1M return
- +25.25%
- -2.01%
- 1Y return
- -9.34%
- -6.14%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- NYSE
- IPO
- 1987
- 2013
- News (4w)
- 9
- 12
- Recent ratings
- 16
- 8
CONMED Corporation
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures worldwide. It offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.
Latest CNMD
- SEC Form 4 filed by Executive Vice President & CFO Gallagher John E
- New insider Gallagher John E claimed no ownership of stock in the company (SEC Form 3)
- BMO Capital Markets initiated coverage on CONMED with a new price target
- SEC Form 4 filed by Director Martin Celine Christine
- SEC Form 4 filed by Director Mirviss Jeffrey B.
- New insider Mirviss Jeffrey B. claimed no ownership of stock in the company (SEC Form 3)
- New insider Martin Celine Christine claimed no ownership of stock in the company (SEC Form 3)
- CONMED Corporation to Report Second Quarter 2026 Financial Results on July 29, 2026
- CONMED downgraded by BofA Securities with a new price target
- CONMED Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure
Latest PRKS
- UNITED PARKS & RESORTS INC. ANNOUNCES SECOND QUARTER 2026 EARNINGS RELEASE DATE AND CONFERENCE CALL INFORMATION
- Northcoast initiated coverage on United Parks & Resorts Inc.
- Large owner Hill Path Capital Partners Co-Investment S Lp was granted 1,821 shares (SEC Form 4)
- Large owner Hill Path Capital Partners Lp was granted 1,821 shares (SEC Form 4)
- Director Chambers James P. was granted 1,098 shares, increasing direct ownership by 2% to 65,558 units (SEC Form 4)
- Director Gray William was granted 1,258 shares, increasing direct ownership by 2% to 76,721 units (SEC Form 4)
- Director Hartnett Timothy was granted 1,821 shares, increasing direct ownership by 2% to 81,378 units (SEC Form 4)
- Director Lipman Nathaniel was granted 207 shares, increasing direct ownership by 1% to 20,316 units (SEC Form 4)
- Director Schaefer Kimberly was granted 415 shares, increasing direct ownership by 0.98% to 42,740 units (SEC Form 4)
- Director Narang Neha Jogani was granted 830 shares, increasing direct ownership by 1% to 57,376 units (SEC Form 4)